Cargando…

ABC Transporters and Cancer /

ABC Transporters and Cancer provides invaluable information on the exciting and fast-moving field of cancer research. Here, outstanding and original reviews are presented on a variety of topics. This volume covers ABC transporters and cancer, and is suitable for researchers and students alike.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Schuetz, John D. (Editor ), Ishikawa, Toshihisa (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Elsevier Ltd., 2015.
Edición:First edition.
Colección:Advances in cancer research ; v. 125.
Temas:
Acceso en línea:Texto completo
Texto completo
Texto completo
Tabla de Contenidos:
  • Front Cover; ABC Transporters and Cancer; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition; 1. Introduction to Apical ABC Transporters; 2. Impact of Apical ABC Transporters on Intestinal Absorption of Oral Chemotherapeutic Drugs; 2.1. Apical ABC transporters affecting the oral bioavailability of taxanes; 2.1.1. ABCB1 and oral taxane availability; 2.1.2. ABCC2 and oral taxane availability; 2.1.3. ABCB1 inhibitors to improve taxane oral availability.
  • 2.1.4. Assessing CNS toxicity risks of using ABCB1 inhibitors to improve oral taxane availability2.1.5. Possible effects of ABCB1 inhibitors on enhancing taxane antitumor efficacy; 2.2. Apical ABC transporters in the oral bioavailability of rationally designed anticancer drugs; 2.2.1. Tyrosine kinase inhibitors; 2.2.2. PARP inhibitors; 2.2.3. Chemical inhibition of transporters to increase oral availability of rationally designed anticancer drugs; 2.2.4. Importance of the sensitivity and specificity of in vitro assays used to assess ABC transporter substrates.
  • 3. Impact of Apical ABC Transporters on Brain Disposition of Oral Chemotherapeutic Drugs3.1. Does the BBB matter in drug delivery to brain tumors?; 3.2. Apical efflux transporters in the BBB affecting brain accumulation of anticancer drugs; 3.2.1. Drugs affected mostly by Abcb1a but also by Abcg2 in their brain accumulation; 3.2.2. Drugs only affected by Abcb1a in their brain accumulation; 3.2.3. Drugs affected mostly by Abcg2 but also by Abcb1a in their brain accumulation; 3.2.4. Three different apical BBB ABC efflux transporters affect brain accumulation of some camptothecins.
  • 3.2.5. Models to explain the disproportionate effect of combined deficiency of Abcb1 and Abcg2 on brain accumulation of s ... 3.2.6. Why are many rationally designed anticancer drugs still ABCB1 and/or ABCG2 substrates?; 3.2.7. Limitations of knockout mouse models to study ABC transporter functions at the BBB; 3.2.8. Tissue and cellular context may affect the in vivo impact of apical ABC efflux transporters; 3.2.9. Use of chemical inhibitors to enhance brain accumulation of ABC transporter substrate drugs; 4. Concluding Remarks; References.
  • Chapter 2: Regulation of ABC Transporters Blood-Brain Barrier: The Good, the Bad, and the Ugly1. Introduction; 2. Blood-Brain Barriers; 2.1. Assessing blood-brain barrier function; 3. ABC Transporters at the Blood-Brain Barrier; 4. The Bad and the Ugly: Mechanisms that Increase Transporter Expression and Reduce Drug Delivery to the CNS; 4.1. Xenobiotic-activated transcription factors; 4.2. Stress-activated transcription factors; 4.3. Disease; 5. The Good: Mechanisms that Reduce Transporter Activity/Expression and Have the Potential to Improve Drug Delivery to th ... ; 5.1. P-glycoprotein.